Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TRPV1 | Q8NER1 | 7/20 | 0.47 |
| ▸ | BCDIN3D | Q7Z5W3 | 8/20 | 0.43 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.41 |
| ▸ | NPC1 | O15118 | 1/20 | 0.39 |
| ▸ | RAB9A | P51151 | 1/20 | 0.39 |
| ▸ | BRAF | P15056 | 1/20 | 0.38 |
| ▸ | MAOA | P21397 | 1/20 | 0.38 |
| ▸ | MAOB | P27338 | 1/20 | 0.38 |
| ▸ | PTK2 | Q05397 | 1/20 | 0.37 |
| ▸ | PTK2B | Q14289 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4158324 | 0.83 | TRPV1 (0.59) | TRPV1BCDIN3D | |
| SCHEMBL4159110 | 0.81 | TRPV1 (0.58) | TRPV1BCDIN3D | |
| SCHEMBL4162708 | 0.79 | TRPV1 (0.44) | TRPV1BCDIN3D | |
| SCHEMBL4167024 | 0.78 | TRPV1 (0.54) | TRPV1 | |
| SCHEMBL4165766 | 0.77 | TRPV1 (0.44) | TRPV1 | |
| SCHEMBL4165731 | 0.77 | TRPV1 (0.42) | TRPV1BCDIN3D | |
| SCHEMBL13801584 | 0.77 | TRPV1 (0.49) | TRPV1KCNH2NPC1RAB9APTK2 | |
| SCHEMBL4154239 | 0.75 | TRPV1 (0.45) | TRPV1BCDIN3D | |
| SCHEMBL4166871 | 0.75 | TRPV1 (0.59) | TRPV1 | |
| SCHEMBL4205834 | 0.75 | TRPV1 (0.53) | TRPV1KCNH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090156598-A1 | Imidazolopyrimidine modulators of TRPV1 | JANSSEN PHARMACEUTICA NV (BE) | 2009-06-18 | — | — | US | claimed |
| US-20090156598-A1 | Imidazolopyrimidine modulators of TRPV1 | JANSSEN PHARMACEUTICA NV (BE) | 2009-06-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090156598-A1 | Imidazolopyrimidine modulators of TRPV1 | TRPV1, TRPV2, TRPV5 | TRPV1 1/4885BCDIN3D 1708/4885KCNH2 300/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.